PAREXEL

PAREXEL International is a growing, fast-paced, global Clinical Research Organization (CRO) that has helped bring to market 49 of the top 50 selling pharmaceuticals. In fact, we have worked with all 10 of the world's top 10 pharmaceutical companies.

About Authors:
V. Ravi Chandra
Research Associate
Parexel
B.Pharmacy from Priyadarshini College of pharmacy,
Osmania University,
Hyderabad, AP, INDIA

Abstract:
Huntington's disease is an intricate illness. It is a neurodegenerative, insidious disorder-which means it is harmful and fatal but gradually. The onset of the disease is very late to diagnose the disease. Huntington's disease (HD) also called as ‘Huntington’s Chorea’. Chorea means dance in Greek, which is aftereffect of genetically programmed degeneration of brain cells, called neurons, in certain areas of the brain. This degeneration causes uncontrolled movements, loss of intellectual faculties, and emotional disturbance. By choreic movement physically we can diagnose HD. HD is also a familial disease, passed from parent to child through a mutation in the normal gene. Attempts to study early disease are not unique in neurology (e.g., mild cognitive impairment and vascular cognitive impairment), but studying otherwise healthy-appearing individuals who have nearly 99% certainty of manifesting the symptoms of brain disease does provide distinct but valuable information about the true natural history of the disease. A genetic test, coupled with a complete medical history and neurological and laboratory tests, helps physicians diagnose HD. Presymptomic testing is available for individuals who are at risk for carrying the HD gene. HD occurs in about one out of every 10,000 Caucasian individuals. In India, the cases are unknown because of failure of doctors to diagnose HD as they never seen HD in their practice. Approximately 2.5 times more individuals are at risk for the disorder because of the midlife peak in age at onset.

PAREXEL has supported the Bio-Tech and Pharmaceutical industries in helping the development of new drugs and treatments on a global basis. As a leading global biopharmaceutical service provider, they supply knowledge-based contract research, medical communications and consulting services across a broad range of therapeutic areas to the worldwide pharmaceutical, biotechnology and medical device industries.

PAREXEL has developed significant expertise to assist clients in the worldwide pharmaceutical, biotechnology and medical device industries with the development and launch of their products in order to bring safe and effective treatments to the global marketplace for the patients who need them. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 54 countries around the world, and has over 9,500 employees.